Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

The Real Truth About Gluten, Grains, And Weight Loss

Going back to basics, grains are wheat, cereals, corn, rice, rye, barley and couscous. They are found in bread, cereal, pasta, bagels, rolls, muffins, crackers, biscuits, pastries, corn, tortilla chips, lager, soy sauce, some canned soups, lots of ready meals – start to read the ingredients labels! Firstly, if eating the processed or white versions […]

Read More »

ImmunoCellular Therapeutics Ltd. Enters Into Manufacturing Agreement With A Caladrius Biosciences Company, For US Production Of ICT-107 For Phase 3 Registration Trial

LOS ANGELES, June 15, 2015 /PRNewswire/ — ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced the selection of PCT, LLC, a subsidiary of Caladrius Biosciences, Inc. (“Caladrius”) (NASDAQ:CLBS), as the US manufacturer for ImmunoCellular’s ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the […]

Read More »

8 Things That Happen When You Finally Stop Drinking Diet Soda

You’ve decided to give up diet soda—good idea! Maybe you weren’t hitting your weight-loss goals or couldn’t stomach that long list of ingredients anymore. Or perhaps you heard one too many times that it’s just not good for you. Whatever the reason, eliminating diet soda from your diet will improve your health from head to […]

Read More »

Avalon and GlaxoSmithKline Bankroll Three More Biotech Startups

The three new startups, Adrenergics, CadheRx Therapeutics and Calporta Therapeutics, will each receive $10 million in the startup funds, as well as plus research support to help advance their work in developing new treatments for heart disease, cancer and certain genetic disorders. The funding is part of a two-year-old $495 million partnership between the England-based […]

Read More »

Ex-AstraZeneca PLC CMO Takes Helm at Tiny Syndax

Syndax Appoints Dr. Briggs W. Morrison as Chief Executive Officer and Michael A. Metzger as President and Chief Operating Officer New Executive Team Will Intensify Focus on Innovation and Leadership in Immuno-oncology WALTHAM, Mass., June 15, 2015 /PRNewswire/ — Syndax Pharmaceuticals, Inc., a privately held oncology company, announced today that Briggs W. Morrison, M.D. is […]

Read More »

Nutrinia Granted FDA Orphan Designation For NTRA-9620 For Short Bowel Syndrome

RAMAT-GAN, Israel, June 15, 2015 /PRNewswire/ — Nutrinia, developing therapies to treat rare gastrointestinal disorders, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the company’s orally-administered drug for treating short bowel syndrome (SBS) in patients of all ages. Nutrinia plans to begin a pivotal clinical trial in this indication. […]

Read More »

Matinas BioPharma’s MAT9001 Demonstrates Superiority In Reducing Triglycerides, Lipids, Apolipoproteins And PCSK9 Levels In Head-To-Head Study With Vascepa

BEDMINSTER, N.J., June 15, 2015 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company, announced the presentation of data from a head-to-head study that showed MAT9001, a prescription-only omega-3 fatty acid-based composition under development for the treatment of hypertriglyceridemia, demonstrated superiority versus Vascepa® (icosapent ethyl) in reducing lipids, triglycerides, apolipoproteins and PCSK9 […]

Read More »

Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In Elderly Patients With AML

VIENNA, June 15, 2015 /PRNewswire/ — CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted […]

Read More »

Taiho Pharmaceutical Co. Ltd. and Servier Enter Into License Agreement for Development and Commercialization of Oral Anticancer Drug TAS-102 in Europe

TOKYO, June 15, 2015 /PRNewswire/ — Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries. Taiho Pharmaceutical Co., Ltd. retains the right […]

Read More »

Smoke – Less: Nicofi Unveils New Alternative to Smoking with a Fast-Acting Pure Nicotine Tablet

MIAMI–(BUSINESS WIRE)–Nicofi™ announced the launch of a revolutionary patented, fast-acting dissolvable nicotine tablet intended for use as an alternative to smoking. Nicofi is a small sublingual tablet made from pure nicotine and other high-quality ingredients that allows smokers to quickly enjoy nicotine in any situation, especially when they are unable to smoke a cigarette or […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom